Prevalence of the metabolic syndrome in psoriasis: results from the National Health and Nutrition Examination Survey, 2003-2006.
暂无分享,去创建一个
[1] D. Veale,et al. Cardiovascular Disease and Risk Factors in Patients with Psoriasis and Psoriatic Arthritis , 2010, The Journal of Rheumatology.
[2] L. Hsu,et al. Insulin resistance is associated with C-reactive protein independent of abdominal obesity in nondiabetic Taiwanese. , 2010, Metabolism: clinical and experimental.
[3] F. Aubin,et al. Cardiovascular risk factors in patients with plaque psoriasis: a systematic review of epidemiological studies , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] Andrea B Troxel,et al. Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. , 2010, European heart journal.
[5] A. Qureshi,et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. , 2009, Archives of dermatology.
[6] J. Gelfand,et al. The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. , 2009, Journal of the American Academy of Dermatology.
[7] Giampiero Girolomoni,et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. , 2008, The American journal of clinical nutrition.
[8] J. Gelfand,et al. Psoriasis and metabolic disease: epidemiology and pathophysiology , 2008, Current opinion in rheumatology.
[9] S. Chimenti,et al. Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. , 2008, Pharmacological research.
[10] P. Gisondi,et al. Anti–tumour necrosis factor‐α therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.
[11] B. Thiers. Obesity, Waist Circumference, Weight Change, and the Risk of Psoriasis in Women: Nurses' Health Study II , 2008 .
[12] Jonathan Shapiro,et al. Psoriasis and dyslipidaemia: a population-based study. , 2008, Acta dermato-venereologica.
[13] Andrea B Troxel,et al. The risk of mortality in patients with psoriasis: results from a population-based study. , 2007, Archives of dermatology.
[14] R. Testa,et al. Effect of Etanercept on Insulin Sensitivity in Nine Patients with Psoriasis , 2007, International journal of immunopathology and pharmacology.
[15] E. Martínez-Abundis,et al. Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus , 2007, Archives of Dermatological Research.
[16] Hyon K. Choi,et al. Obesity, waist circumference, weight change, and the risk of psoriasis in women: Nurses' Health Study II. , 2007, Archives of internal medicine.
[17] S. Piaserico,et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital‐based case–control study , 2007, The British journal of dermatology.
[18] Daniel B. Shin,et al. Prevalence of cardiovascular risk factors in patients with psoriasis. , 2022, Central European journal of public health.
[19] Daniel B. Shin,et al. Risk of myocardial infarction in patients with psoriasis. , 2006, JAMA.
[20] M. Weichenthal,et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis , 2006, Archives of Dermatological Research.
[21] S. Feldman,et al. Quality of life in patients with psoriasis , 2006, Health and quality of life outcomes.
[22] D. Margolis,et al. Prevalence and treatment of psoriasis in the United Kingdom: a population-based study. , 2005, Archives of dermatology.
[23] Fernando Costa,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. , 2005, Circulation.
[24] E. Ford. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. , 2005, Diabetes care.
[25] R. Stern,et al. The prevalence of psoriasis in African Americans: results from a population-based study. , 2005, Journal of the American Academy of Dermatology.
[26] David J Margolis,et al. Determinants of quality of life in patients with psoriasis: a study from the US population. , 2004, Journal of the American Academy of Dermatology.
[27] Samuel Szomstein,et al. Psoriasis Remission after Laparoscopic Roux-En-Y Gastric Bypass for Morbid Obesity , 2004, Obesity surgery.
[28] J. Tuomilehto,et al. Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. , 2004, Archives of internal medicine.
[29] David J Margolis,et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. , 2004, The journal of investigative dermatology. Symposium proceedings.
[30] J. Sowers. Obesity as a cardiovascular risk factor. , 2003, The American journal of medicine.
[31] E. Martínez-Abundis,et al. Lipid profile, insulin secretion, and insulin sensitivity in psoriasis. , 2003, Journal of the American Academy of Dermatology.
[32] J. Mckenney,et al. National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) , 2002 .
[33] W. Dietz,et al. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. , 2002, JAMA.
[34] S. Grundy,et al. National Cholesterol Education Program Third Report of the National Cholesterol Education Program ( NCEP ) Expert Panel on Detection , Evaluation , and Treatment of High Blood Cholesterol in Adults ( Adult Treatment Panel III ) Final Report , 2022 .
[35] J. Manson,et al. A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. , 2000, The American journal of medicine.
[36] S. Haffner,et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). , 2000, Circulation.
[37] P. Zimmet,et al. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation , 1998, Diabetic medicine : a journal of the British Diabetic Association.
[38] J. Koo. Population-based epidemiologic study of psoriasis with emphasis on quality of life assessment. , 1996, Dermatologic clinics.
[39] G. Reaven,et al. Insulin resistance and cigarette smoking , 1992, The Lancet.
[40] S. E. Stenvold,et al. Low prevalence of psoriasis in Norwegian lapps. , 1985, Acta dermato-venereologica.
[41] A. Green,et al. The prevalence of psoriasis in Denmark. , 1981, Acta dermato-venereologica.